Results 41 to 50 of about 21,457 (218)

Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy

Haematologica, 2008
We analyzed the effect of hydroxyurea on the JAK2V617F allelic ratio (%JAK2V617F), measured in purified blood granulocytes, of patients with polycythemia vera and essential thrombocythemia.
François Girodon, Céline Schaeffer, Cédric Cleyrat, Morgane Mounier, Ingrid Lafont, Frédéric Dos Santos, Aurélie Vidal, Marc Maynadié, Sylvie Hermouet   +8 more
doaj   +1 more source

Thrombospondin in essential thrombocythemia [PDF]

Blood, 1986
Abstract Essential thrombocythemia is a myeloproliferative disorder characterized by frequent bleeding and thrombotic complications. On a molecular level, two abnormalities of platelet thrombospondin have been identified: abnormal glycosylation of the intact 185,000-dalton chain has been detected and a shortened form of the ...
J, Lawler, A M, Cohen, F C, Chao, D J, Moriarty   +3 more
openaire   +3 more sources

Emerging treatments for essential thrombocythemia

, 2011
Steven Okoli, Claire HarrisonDepartment of Haematology, Guy's and St Thomas' NHS Foundation Trust, Great Maze Pond, London, UKAbstract: In 1934, Epstein and Goedel used the term hemorrhagic thrombocythemia to describe a disorder ...
Okoli S, Harrison C, null Okoli, Claire Harrison   +3 more
core   +1 more source

Isolated ten-eleven translocation 2 positive in triple negative essential thrombocythemia: Case report and literature review

SAGE Open Medical Case Reports, 2021
Essential thrombocythemia is one of the famous diseases under the category of myeloproliferative disorder. It is an end result of a genetic mutation of one or more of the most frequent oncogenes such as Janos kinase 2 (JAK2), MPL proto-oncogene ...
Rehab Y AL-Ansari, Dena Al Otaibi, Nourah Al Hudaithi, Leena Abdalla   +3 more
doaj   +1 more source

Late‐Onset Chorea in JAK2‐Associated Essential Thrombocythemia [PDF]

, 2021
Somatic mutations in JAK2 are associated with chronic myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis (PMF).
Mulroy, E, Di Lazzaro, G, Giulia Di Lazzaro, Koya Kutty, Shahedah, Shahedah, KK, Di Lazzaro, Giulia, Magrinelli, F, Mulroy, Eoin, Latorre, A, Anna Latorre, Shahedah Koya Kutty, Francesca Magrinelli, Bhatia, KP, Latorre, Anna, Eoin Mulroy, Bhatia, Kailash P, Kailash P. Bhatia, Magrinelli, Francesca   +17 more
core   +1 more source

Essential thrombocythemia (ET) [PDF]

Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011
The disease is a chronic myeloproliferative disorder originating from a mutated pluripotent stem cell capable of producing red blood cells, granulocytes and megakaryocytes. In some cases, B-lymphocyte involvement by the clonal proliferation was documented.
CUNEO, Antonio, CAVAZZINI, Francesco
openaire   +2 more sources

Recurrent thrombosis of splanchnic and lower extremity arteries with essential thrombocythemia

SAGE Open Medical Case Reports, 2019
Essential thrombocythemia is a myeloproliferative neoplasm characterized by platelet aggregation and thrombosis. Clinically, essential thrombocythemia increases the risk of both thrombosis and bleeding. Essential thrombocythemia is more involved in micro-
Sung Min Jung, Heungman Jun
doaj   +1 more source

Ruxolitinib Pharmacokinetics and Exposure–Toxicity Relationship in Hematologic Malignancies and Immune‐Mediated Diseases: A Prospective Observational Study

Clinical Pharmacology &Therapeutics, EarlyView.
Ruxolitinib pharmacokinetics (PK) has been characterized in clinical trials but remains poorly documented in real‐world practice. This project aimed to investigate ruxolitinib PK in routine clinical practice, identify factors driving its variability, and explore exposure–response relationships to assess the potential role of therapeutic drug monitoring.
Jérémie Tachet, Sara C. Meyer, Francesco Grandoni, Emmanuel Haefliger, Monika Nagy‐Hulliger, Jörg P. Halter, Jakob R. Passweg, David Haefliger, Carine Bardinet, Laurent A. Decosterd, Monia Guidi, François R. Girardin   +11 more
wiley   +1 more source

A Case of Myeloproliferative Neoplasm‐Associated Glomerulopathy in a Patient With Myelofibrosis

Clinical Case Reports
Myeloproliferative neoplasm (MPN)‐related glomerulopathy is a rare, late complication of MPN. Mesangial matrix expansion seems to be the histopathological hallmark. Proteinuria may not always be present.
Saskia Leibowitz, Michelle Spanevello, Leo Francis, Prianka Puri, Kirsten Hepburn   +4 more
doaj   +1 more source

The German ONKOPEDIA Guideline for Myelofibrosis in 2025—Recommendations of an MPN Expert Panel of the German Society for Hematology and Oncology (DGHO)

International Journal of Cancer, EarlyView.
ABSTRACT The recently published ONKOPEDIA guideline on myelofibrosis, issued under the auspices of the German Society of Hematology and Oncology (DGHO), provides an updated, evidence‐based framework for the diagnosis and management of this rare, chronic myeloproliferative neoplasm.
Martin Griesshammer, Haifa Kathrin Al‐Ali, Gabriela M. Baerlocher, Konstanze Döhner, Steffen Koschmieder, Nicolaus Kröger, Petro E. Petrides, Dominik Wolf, Florian H. Heidel   +8 more
wiley   +1 more source